London Plane Tree (Pla a 1) IgE Test · Blood

If you live in a city, you probably walk past London plane trees every day. They line streets across Europe, Australia, parts of Asia, and large American cities. Their pollen is also one of the more underrecognized triggers of seasonal allergies, and a standard pollen skin test or a broad pollen panel often cannot tell you whether this particular tree is the actual problem.

This test looks for IgE (immunoglobulin E, an antibody your body makes during allergic reactions) directed at Pla a 1, one of the named protein pieces of London plane tree pollen. The result helps separate true plane tree allergy from cross-reactions with grass, birch, or weed pollen that can muddy a basic allergy workup.

What This Test Actually Measures

The Pla a 1 (Platanus acerifolia allergen 1) test measures IgE antibodies in your blood that specifically bind to one molecular piece of London plane tree pollen. IgE antibodies are made by certain immune cells (B lymphocytes) after exposure to an allergen, and detecting them means your immune system has been sensitized to that exact protein.

This is a component-resolved test, meaning it targets a single defined protein rather than a crude pollen extract. A detectable result means your immune system recognizes Pla a 1; an undetectable result argues against this molecule being a driver of your symptoms.

Pla a 1 Is a Minor Player in Plane Tree Allergy

Here is the most useful fact for interpreting your result. In a large Italian cohort of 939 plane tree allergic patients tested by molecular methods, roughly 72% had IgE to Pla a 3, about 54% had IgE to Pla a 2, and only about 11% had IgE to Pla a 1. Pla a 1 was named first by chronology, not by importance.

What this means for you: a positive Pla a 1 result is meaningful, but a negative Pla a 1 result does not rule out plane tree allergy. The clinically dominant components for respiratory plane tree allergy and food cross-reactivity are Pla a 2 and Pla a 3.

Respiratory Allergy Risk

London plane tree pollen is recognized as a cause of allergic rhinitis, conjunctivitis, and asthma during tree pollen season. Component testing across European and Chinese cohorts shows that plane tree sensitization is closely tied to respiratory symptoms, with multiple-pollen sensitization producing worse nasal and ocular symptom scores than single-pollen sensitization.

In studies that broke plane tree allergy down into components, respiratory symptoms tracked most closely with Pla a 2 reactivity rather than Pla a 1. If your Pla a 1 is positive, the larger plane tree component panel becomes more important than the Pla a 1 number on its own.

Oral Allergy and Food Cross-Reactivity

Plane tree pollen sensitization is linked to food reactions in a significant minority of patients. In a Spanish cohort, about 52% of people sensitized to Platanus acerifolia pollen also had food allergy, most often to hazelnut, peach, apple, peanut, corn, chickpea, and lettuce. The mechanism is cross-reactivity between pollen proteins and similar proteins in plant foods.

Within plane tree components, Pla a 3 (a lipid transfer protein) is the component most associated with both local mouth symptoms and more serious systemic food reactions. If you notice itching, tingling, or swelling after eating fresh fruits or nuts, plane tree component testing including Pla a 3 alongside Pla a 1 is the most informative workup.

Why This Matters for Allergy Shots

Molecular allergy testing changes immunotherapy decisions. In the INMUNOCAT study of 300 polysensitized patients, switching from extract-based testing to a 112-component molecular panel that included Pla a 1, 2, and 3 changed allergen immunotherapy prescriptions in 51% of cases and increased the share of patients getting tailored immunotherapy from 39% to 65%.

If you are considering allergy shots or sublingual immunotherapy, knowing which specific plane tree components you react to (rather than just "plane tree extract is positive") helps your allergist build a more targeted treatment plan and avoid wasting years on the wrong allergen mix.

Polysensitization Is the Norm, Not the Exception

Plane tree sensitization almost never stands alone. In a Spanish study of pollen-allergic patients, every single person sensitized to Platanus pollen was also sensitized to at least one other pollen. Profilin and other panallergens (proteins shared across many plants) can also confuse a broad pollen panel by causing positive results that don't reflect a real clinical allergy.

A Pla a 1 result is most useful when interpreted alongside other tree, grass, and weed components, plus markers of panallergen reactivity. By itself, it answers one narrow question; in context, it helps unmask which pollens are truly driving your symptoms.

Tracking Your Trend

A single specific IgE reading is a snapshot of your current sensitization, but allergy biology shifts over time. New sensitizations develop, existing ones can fade, and immunotherapy can change the antibody picture. Tracking your Pla a 1 alongside the broader plane tree component panel gives you a trajectory rather than an isolated data point.

A practical cadence: establish a baseline now if you have spring or early summer respiratory symptoms, repeat in 6 to 12 months if you start immunotherapy or significantly change your environment, and revisit at least every 1 to 2 years to watch the pattern. If you start having new food reactions, repeat earlier and include Pla a 2 and Pla a 3.

What to Do With an Unexpected Result

If your Pla a 1 is positive and you have spring respiratory symptoms in an area with London plane trees, the natural next step is a fuller plane tree component panel (Pla a 2 and Pla a 3), plus components for other locally common trees (birch Bet v 1, olive, cypress), grass (Phleum), and weeds. This builds out the molecular allergy picture and helps an allergist decide whether immunotherapy makes sense.

If your Pla a 1 is negative but you still have clear seasonal symptoms when plane trees pollinate, do not stop there. Because Pla a 1 captures only about 1 in 10 plane tree allergic patients in molecular cohorts, ordering Pla a 2 and Pla a 3 (and considering a panallergen panel for profilin and lipid transfer proteins) is a reasonable next step before concluding that plane tree is not the trigger. A consultation with an allergist trained in component-resolved diagnostics is worthwhile when results and symptoms do not match cleanly.

When Results Can Be Misleading

Component IgE testing is generally more specific than crude pollen extract testing, but a few factors can still distort interpretation:

• Panallergens like cyclophilin and profilin: IgE against these widely shared plant proteins can cause positive results to many pollen extracts, including plane tree. A component test like Pla a 1 cuts through some of this noise, but other components on the panel can still be cross-reactive.
• Sensitization without symptoms: Studies in adolescents found that more than half of unselected teens had IgE to at least one allergen, often without any clinical allergic disease. A positive Pla a 1 in someone with no symptoms during plane tree season may not be clinically meaningful on its own.
• Assay platform differences: Different labs use different methods (singleplex assays such as ImmunoCAP versus multiplex chips such as ISAC). The cutoff for positivity and the absolute numbers can vary between platforms, so trending serial results works best when you stay with the same lab and method.

Who This Test Helps Most

This test is most useful for adults and children with seasonal respiratory symptoms that line up with tree pollen season, particularly in cities and regions where London plane trees are a dominant urban tree. It also adds value for people with pollen-food syndrome symptoms (mouth itching or swelling from fresh fruits and nuts) where pinning down the primary pollen sensitization matters.

It is less useful as a screening test for people with no symptoms. The available evidence does not show that testing apparently healthy adults for Pla a 1 changes outcomes or detects disease earlier in any meaningful way. The test pays off when it can directly influence a treatment decision, especially around immunotherapy.